Contrast Agent Diatrizoic Acid CAS 50978-11-5 Benzoic Acid

Product Description

 Diatrizoic Acid API USP EP Amidotrizoic Acid Dihydate CAS No. 50978-11-5 Contrast Agent

Fuction: Amidotrizoic Acid Dihydate is used for producing the radiopaque contrast agent for intravascular use named as Diatrizoate Meglumine and Diatrizoate Sodium Injection or Diatrizoate Meglumine Injection.

Mechanism of action
Diatrizoate is an iodine-containing X-ray contrast agent. Iodated contrast agents were among the first contrast agents developed. Iodine is known to be particular electron-dense and to effectively scatter or stop X-rays. A good contrast agent requires a high density of electron-dense atoms. Therefore, the more iodine, the more "dense" the x-ray effect. Iodine based contrast media are water soluble and harmless to the body. These contrast agents are sold as clear colorless water solutions, the concentration is usually expressed as mg I/ml. Modern iodinated contrast agents can be used almost anywhere in the body. Most often they are used intravenously, but for various purposes they can also be used intraarterially, intrathecally (the spine) and intraabdominally - just about any body cavity or potential space.

Who we are:

XI’AN LIBANG PHARMACEUTICAL CO.,LTD. founded in 1996 with a location in Xi’an City of China, the center of the northwest pharmaceutical industry, is specialized in research, development, production and distribution of specialty pharmaceutical products. As the first and also largest supplier of generic Propofol in China, LIBANG started its business and subsequently launched a broad portfolio finished dosage forms covering anesthetics, cardiovascular, antineoplastic, clinical nutrition etc.

With more than 20 years growth, LIBANG has transformed into an integrated health care solution provider, LIBANG HEALTHCARE GROUP, with diversified fields covering high value-added APIs, pharmaceutical excipients, prescription drugs, OTC products, biomedicine, medical devices.

LIBANG is a technology-driven firm, with more than 8% of the annual sales revenues devoted to research and innovation, establishing a unique R&D platform to proactively follow the latest pharmaceutical technology frontier.

LIBANG now is one of Top 100 China’s Pharmaceutical Industries and also listed in the Top 20 The Most Potential Chinese Pharmaceuticals that was rated by the IMS Health.